Ferguson Wellman Capital Management Inc. Invests $26,000 in Tilray Inc (NASDAQ:TLRY)

Ferguson Wellman Capital Management Inc. bought a new position in shares of Tilray Inc (NASDAQ:TLRY) during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 14,863 shares of the company’s stock, valued at approximately $26,000.

Other institutional investors also recently modified their holdings of the company. Bank of Montreal Can raised its position in shares of Tilray by 19.6% during the second quarter. Bank of Montreal Can now owns 2,169,100 shares of the company’s stock worth $3,622,000 after purchasing an additional 355,778 shares during the period. Lazard Asset Management LLC bought a new stake in Tilray during the first quarter worth $118,000. Avantax Advisory Services Inc. grew its holdings in Tilray by 46.2% during the first quarter. Avantax Advisory Services Inc. now owns 53,110 shares of the company’s stock worth $131,000 after buying an additional 16,792 shares in the last quarter. Creative Planning grew its holdings in Tilray by 36.6% during the third quarter. Creative Planning now owns 141,921 shares of the company’s stock worth $250,000 after buying an additional 38,054 shares in the last quarter. Finally, Concurrent Investment Advisors LLC bought a new stake in Tilray during the first quarter worth $75,000. 9.35% of the stock is owned by institutional investors and hedge funds.

Tilray Trading Down 4.2 %

Shares of NASDAQ:TLRY opened at $1.38 on Friday. The company has a debt-to-equity ratio of 0.08, a quick ratio of 1.57 and a current ratio of 2.47. The business has a fifty day moving average price of $1.66 and a two-hundred day moving average price of $1.78. Tilray Inc has a 1 year low of $1.36 and a 1 year high of $2.97.

Tilray (NASDAQ:TLRY) last announced its quarterly earnings data on Thursday, October 10th. The company reported ($0.04) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.04). The firm had revenue of $200.00 million during the quarter, compared to the consensus estimate of $218.70 million. Tilray had a negative return on equity of 2.00% and a negative net margin of 26.79%. The business’s revenue for the quarter was up 13.0% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.10) EPS. Sell-side analysts anticipate that Tilray Inc will post -0.14 EPS for the current year.

Analysts Set New Price Targets

Separately, Roth Mkm decreased their price target on Tilray from $2.00 to $1.75 and set a “neutral” rating for the company in a report on Friday, October 11th.

Tilray Profile

Tilray, Inc engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc is headquartered in Canada.